Seeking Alpha

Celgene (CELG) is one of two firms other than GSK that are considering buying Human Genome...

Celgene (CELG) is one of two firms other than GSK that are considering buying Human Genome (HGSI) and are holding talks with the company, Reuters reports. There's no word on who the second suitor is, although any deal would most likely be a merger of equals. With Human Genome holding an auction, the deadline for bids is July 16.
From other sites
Comments (1)
  • Todd Johnson
    , contributor
    Comments (6954) | Send Message
     
    $GSK owns $HGSI. $CELG is supposed to be stacked with their own drugs,no?
    8 Jul 2012, 07:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs